Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 7;29(1):1-18.
doi: 10.3748/wjg.v29.i1.1.

Emerging roles of non-coding RNAs in colorectal cancer oxaliplatin resistance and liquid biopsy potential

Zheng-Dong Luo  1 , Yi-Feng Wang  1 , Yu-Xiao Zhao  1 , Long-Chen Yu  1 , Tian Li  1 , Ying-Jing Fan  1 , Shun-Jie Zeng  1 , Yan-Li Zhang  2 , Yi Zhang  1 , Xin Zhang  3
Affiliations
Review

Emerging roles of non-coding RNAs in colorectal cancer oxaliplatin resistance and liquid biopsy potential

Zheng-Dong Luo et al. World J Gastroenterol. .

Abstract

Colorectal cancer (CRC) is one of the most common malignancies of the digestive tract, with the annual incidence and mortality increasing consistently. Oxaliplatin-based chemotherapy is a preferred therapeutic regimen for patients with advanced CRC. However, most patients will inevitably develop resistance to oxaliplatin. Many studies have reported that non-coding RNAs (ncRNAs), such as microRNAs, long non-coding RNAs, and circular RNAs, are extensively involved in cancer progression. Moreover, emerging evidence has revealed that ncRNAs mediate chemoresistance to oxaliplatin by transcriptional and post-transcriptional regulation, and by epigenetic modification. In this review, we summarize the mechanisms by which ncRNAs regulate the initiation and development of CRC chemoresistance to oxaliplatin. Furthermore, we investigate the clinical application of ncRNAs as promising biomarkers for liquid CRC biopsy. This review provides new insights into overcoming oxaliplatin resistance in CRC by targeting ncRNAs.

Keywords: Colorectal cancer; Liquid biopsy biomarkers; Non-coding RNAs; Oxaliplatin; Resistance.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All authors declare that we have no other real or potential conflict of interest for this article.

Figures

Figure 1
Figure 1
Classification of non-coding RNAs. Non-coding RNAs can be divided into either small ncRNAs (< 200 nucleotides) or long non-coding RNAs (> 200 nucleotides) based on their length. Among these, small ncRNAs consist of ribosomal RNAs, transfer RNAs, small nucleosome/spliced RNAs, microRNAs, small interfering RNAs, PiWI-Interacting RNAs, and small nucleolar RNAs. Furthermore, the circular RNAs generated in the splicing process of pre-mRNA are also considered to be special ncRNAs. ncRNAs: Non-coding RNAs; lncRNAs: Long non-coding RNAs; rRNAs: Ribosomal RNAs; tRNAs: Transfer RNAs; snRNAs: Small nucleosome/spliced RNAs; miRNAs; MicroRNAs; siRNAs: Small interfering RNAs; piRNAs: PiWI-Interacting RNAs; snoRNAs: Small nucleolar RNAs.
Figure 2
Figure 2
Overview of the mechanisms by which several non-coding RNAs exert oxaliplatin resistance in colorectal cancer. Various microRNAs, long non-coding RNAs, and circular RNAs are up-regulated or down-regulated in colorectal cancer and mediate oxaliplatin resistance via a multitude of mechanisms. These mechanisms include acting as competing endogenous RNAs, generating encoded peptides, regulating autophagy, inducing apoptosis, and interfering with DNA damage and repair. In particular, several non-coding RNAs have been demonstrated to confer oxaliplatin resistance in colorectal cancer cells via exosomes. CRC: Colorectal cancer; lncRNAs: Long non-coding RNAs; miRNAs; MicroRNAs; circRNAs: Circular RNAs.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
    1. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–1480. - PubMed
    1. Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325:669–685. - PubMed
    1. Kanemitsu Y, Shitara K, Mizusawa J, Hamaguchi T, Shida D, Komori K, Ikeda S, Ojima H, Ike H, Shiomi A, Watanabe J, Takii Y, Yamaguchi T, Katsumata K, Ito M, Okuda J, Hyakudomi R, Shimada Y, Katayama H, Fukuda H JCOG Colorectal Cancer Study Group. Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial. J Clin Oncol. 2021;39:1098–1107. - PMC - PubMed
    1. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018;378:1177–1188. - PMC - PubMed

MeSH terms